Pakistan to manufacture Chinese COVID - 19 vaccine
KARACHI – The Searle Company Limited has inked an agreement with a Chinese pharmaceutical giant to manufacture the Covid-19 vaccine in Pakistan.
The leading pharmaceutical company has concluded an exclusive licensing and supply agreement with Livzon Mapharm Inc. for the ‘recombinant novel coronavirus vaccine (V-01)’. It also includes the manufacturing transition of (V-01) in Pakistan.
The Covid-19 vaccine developed by a Chinese firm has shown promising outcomes in phase I and II clinical trials. The phase-Ill clinical study will include numerous countries and register more than 20,000 subjects, with the aim to assess the efficacy of the vaccine.
The V-01 has many advantages including a strong safety profile, high neutralising antibody titre in vivo, long durability, and easy to scale up for manufacturing.